News | June 03, 2022
Mitsubishi Tanabe Pharma America presents 48-week results from phase 3 safety clinical study of Radicava ORS
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
These and many other questions gather worldwide experts of the pharmaceutical industry at the PHARMAP 2022 which takes place in Berlin, Germany on June, 20 - 21, 2022
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
PAYBACK loyalty will be live in 4500 Apollo Pharmacy outlets across India
This expansion announcement came right after raising series B funding of $27 Mn in a round led by Fundamentum Partnership, earlier this month.
Subscribe To Our Newsletter & Stay Updated
